TCOG T5217 trial: A phase II randomized study of SLOG versus modified FOLFIRINOX as the first-line treatment in locally advanced or metastatic pancreatic ductal adenocarcinoma.

被引：6

作者：

Chiang, Nai-Jung

Shan, Yan-Shen

Bai, Li-Yuan

Li, Chung-Pin

Chen, Jen-Shi

Yang, Shih-Hung

Kuo, Yung-Chia

Chao, Yee

Hsieh, Yao-yu

Kao, Hsiang-fong

Hsiao, Chin-Fu

Chen, Li-Tzong

机构：

[1] Natl Hlth Res Inst, Natl Inst Canc Res, Tainan, Taiwan

[2] NCKU, Coll Med, Tainan, Taiwan

[3] NCKUH, Tainan, Taiwan

[4] China Med Univ Hosp, Dept Hematol & Oncol, Taichung, Taiwan

[5] Taipei Vet Gen Hosp, Taipei, Taiwan

[6] Linkou Chang Gung Mem Hosp, Taoyuan, Taiwan

[7] Chang Gung Univ, Taoyuan, Taiwan

[8] Natl Taiwan Univ Hosp, Taipei, Taiwan

[9] Chang Gung Mem Hosp, Div Med Oncol, Dept Internal Med, Taoyuan, Taiwan

[10] Shuan Ho Hosp, Div Hematol & Oncol, New Taipei, Taiwan

[11] Natl Taiwan Univ Hosp, Dept Oncol, Taipei, Taiwan

[12] Natl Hlth Res Inst, Inst Populat Hlth Sci, Miaoli, Taiwan

[13] Natl Hlth Res Inst, Tainan, Taiwan

来源：

关键词：

D O I：

10.1200/JCO.2021.39.15_suppl.4143

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

4143

引用

页数：2